Maze Therapeutics (MAZE) announced the appointment of Misbah Tahir as chief financial officer, CFO, effective immediately. Tahir brings more than 20 years of financial and strategic experience in the biopharmaceutical industry. He most recently served as CFO of IGM Biosciences.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics initiated with a Buy at BTIG
- Maze Therapeutics’ MZE782: Promising Potential in CKD Treatment Through SLC6A19 Inhibition
- Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health
- Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials
- Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782